璩良 - 复旦大学 - 基础医学院

个人简介

教育经历 2011.09 – 2015.07 苏州大学医学部生物技术（免疫工程）专业，本科 2015.09 – 2020.07 北京大学生命科学学院生物化学与分子生物学专业，博士工作经历 2020.07 – 2022.11 北京大学生命科学学院&生物医学前沿创新中心，博士后研究（讲师） 2022.11 – 至今复旦大学基础医学院前沿创新中心&医学系统生物学系，青年研究员获得奖项 2020年北京大学优秀博士学位论文，北京大学 2020年吴瑞奖，美国吴瑞纪念基金会

研究领域

前沿RNA技术与肿瘤免疫治疗新型基因编辑技术与疾病精准治疗

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1. Liang Qu*, Zongyi Yi*, Yong Shen*, Liangru Lin, Feng Chen, Yiyuan Xu, Zeguang Wu, Huixian Tang, Xiaoxue Zhang, Feng Tian, Chunhui Wang, Xia Xiao, Xiaojing Dong, Li Guo, Shuaiyao Lu, Chengyun Yang, Cong Tang, Yun Yang, Wenhai Yu, Junbin Wang, Yanan Zhou, Qing Huang, Ayijiang Yisimayi, Shuo Liu, Weijin Huang, Yunlong Cao, Youchun Wang, Zhuo Zhou, Xiaozhong Peng, Jianwei Wang, Xiaoliang Sunney Xie, Wensheng Wei#. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell. 2022 May 12;185(10):1728-1744.e16. Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971115/ 2. Liang Qu*, Zongyi Yi*, Shiyou Zhu*, Chunhui Wang*, Zhongzheng Cao*, Zhuo Zhou*, Pengfei Yuan*, Ying Yu, Feng Tian, Zhiheng Liu, Ying Bao, Yanxia Zhao, Wensheng Wei#. Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs. Nature Biotechnology, 2019 Sep;37(9):1059-1069. Highlighted by Nature Reviews Drug Discovery: Expanding the RNA-editing toolbox. (2019) Highlighted by Nature Reviews Genetics: Expanding options for RNA based editors. (2019) 入选国家“十三五”科技创新成就展:《新型基因编辑技术》（2021年） Link: https://www.nature.com/articles/s41587-019-0178-z 3. Zongyi Yi*, Liang Qu*, Huixian Tang*, Zhiheng Liu, Ying Liu, Feng Tian, Chunhui Wang, Xiaoxue Zhang, Ziqi Feng, Ying Yu, Pengfei Yuan, Zexuan Yi, Yanxia Zhao, Wensheng Wei#. Engineered circular ADAR-recruiting RNAs increase the efficiency and fidelity of RNA editing in vitro and in vivo. Nature Biotechnology, 2022 Jun;40(6):946-955. Highlighted by Nature Reviews Genetics: In vivo RNA base editing with circular RNAs. (2022) Link: https://www.nature.com/articles/s41587-021-01180-3 4. Chunsheng Dong*#, Liang Qu*, Haoyi Wang, Lin Wei, Yuanshu Dong, Sidong Xiong#. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. Antiviral Research. 2015 Jun;118:110-7. Link: https://pubmed.ncbi.nlm.nih.gov/25843425/